Blastic plasmacytoid dendritic cell neoplasm Pipeline Insights and Emerging Therapies by DelveInsight

Posted on
by

Blastic plasmacytoid dendritic cell neoplasm Pipeline Insights and Emerging Therapies by DelveInsight

 

DelveInsight has launched a new report on Blastic Plasmacytoid Dendritic Cell Neoplasm Pipeline

 

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy of the bone marrow and blood that can affect other organs such as the lymph nodes, spleen, central nervous system, and skin. In fact, skin lesions are present in most patients with BPDCN. These skin lesions are often a deep purple color, and patients often develop multiple lesions. More men than women are diagnosed with BPDCN (~3:1 ratio), and it is most common in patients age 60 years and older. Although BPDCN occurs more frequently in the elderly, the tumor may occur in patients of any age, including pediatric patients.

 

Browse free sample copy- https://www.delveinsight.com/sample-request/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-malignancy-pipeline-insight

 

BK virus Infection Pipeline

 

BPDCN presents with features of both lymphoma and leukemia. Accurate diagnosis of this malignancy has been complicated by a number of factors, including shifting nomenclature over the years –BPDCN has been referred to as agranular CD4+ natural killer cell leukemia, blastic natural killer-cell leukemia/lymphoma and CD4+/CD56+ hematodermic neoplasm.1,4-6 As understanding of the biology and origin of this malignancy has improved, the World Health Organization (WHO) established the term blastic plasmacytoid dendritic cell neoplasm in 2008. BPDCN is currently classified by WHO as a distinct entity within the acute myeloid neoplasms and acute leukemias.

 

Emerging drugs included in the report

  • IMGN632: Immunogen
  • UCART123: Cellectis
  • XmAb14045: Xencor
  • MB 102: MustangBio

 

BK virus Infection Emerging Drugs

The dynamics of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending across the world and expected the launch of emerging therapies during the forecast period of 2020-2030. Companies across the globe are working towards the development of new treatment therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).  There are currently many potential therapies for BPDCN in early-stage clinical trials that target CD123. A few of them have been described below.

 

BK virus Infection Report Scope

  • The Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy.

 

Browse free sample copy- https://www.delveinsight.com/sample-request/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-malignancy-pipeline-insight

 

Table of content 

1. Report Introduction

2. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy 

3. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Current Treatment Patterns

4. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy – DelveInsight’s Analytical Perspective

6. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Late Stage Products (Phase-III)

7. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Discontinued Products

13. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Product Profiles

14. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Key Companies

15. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Key Products

16. Dormant and Discontinued Products

17. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Unmet Needs

18. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Future Perspectives

19. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Analyst Review  

20. Appendix

21. Report Methodology

 

What are the report highlights?

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy.   
  • In the coming years, the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy treatment market. Several potential therapies for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy market size in the coming years. 
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

 

Related Reports

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/